A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
- Conditions
- Ulcerative Colitis (UC)Crohn's Disease
- Interventions
- Drug: Cytochrome P450 (CYP) Substrates
- Registration Number
- NCT04254783
- Lead Sponsor
- AbbVie
- Brief Summary
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. CD may cause tiredness, loose stools with or without bleeding, abdominal pain, weight loss, and fever. This study will evaluate the effect of repeated infusions of risankizumab on the pharmacokinetics of sensitive probe substrates of Cytochrome P450 (CYP) enzymes in participants with moderately to severely active UC or CD.
Risankizumab is an investigational drug being developed to treat trial participants with inflammatory diseases such as UC and CD. The study is split into two periods. In Period 1, participants will receive single oral doses of CYP sensitive probes and in Period 2, participants will receive risankizumab followed by single oral doses of CYP sensitive probes. Around 20 adult participants with moderately to severely active CD or UC will be enrolled in the study across multiple sites worldwide.
In Period 1, participants will receive oral doses of CYP sensitive probes on Day 1. In Period 2, participants will receive risankizumab by intravenous (IV) infusion on Days 1, 29 and 57 followed by oral CYP sensitive probes on Day 64.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests and checking for side effects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
- Confirmed diagnosis of UC or CD for at least 3 months prior to Day -1 (baseline). Appropriate documentation of biopsy results consistent with the diagnosis of CD or UC, in the assessment of the gastroenterologist, must be available.
- Moderately to severely active CD or UC.
- Must have demonstrated intolerance or inadequate response to one or more of the following categories of drugs: aminosalicylates, oral locally acting steroids, systemic steroids, immunomodulators, and/or approved biologic therapies.
- Participant must agree to not use any known inhibitors or inducers of cytochrome P450 within 1 month or 5 half-lives, whichever is greater before each administration of the cocktail probe and until the last pharmacokinetic sample is collected, 7 days after the intake of each probe cocktail.
- History of any clinically significant sensitivity or allergy to any medication or food.
- History of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, pH, or absorption (e.g., celiac disease, gastroparesis, cholecystectomy, vagotomy).
- Positive for COVID-19 infection signs and symptoms.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Cytochrome P450 (CYP) + Risankizumab Cytochrome P450 (CYP) Substrates In Period 1, participants will receive single oral dose of Cytochrome P450 (CYP) substrates on Day 1. In Period 2, three IV doses of risankizumab on Days 1, 29 and 57, followed by single oral dose of CYP substrates on Day 64 will be administered. Cytochrome P450 (CYP) + Risankizumab Risankizumab In Period 1, participants will receive single oral dose of Cytochrome P450 (CYP) substrates on Day 1. In Period 2, three IV doses of risankizumab on Days 1, 29 and 57, followed by single oral dose of CYP substrates on Day 64 will be administered.
- Primary Outcome Measures
Name Time Method Maximum Observed Plasma Concentration (Cmax) of Midazolam Up to 71 Days Maximum observed plasma concentration (Cmax) of Midazolam
AUC From Time 0 to Infinity (AUCinf) of Midazolam Up to 71 Days Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity
Terminal Phase Elimination Rate Constant (β) of Caffeine Up to 71 Days Terminal phase elimination rate constant (β) for Caffeine
Time to Maximum Observed Plasma Concentration (Tmax) of Midazolam Up to 71 Days Time to maximum plasma concentration (Tmax) of Midazolam
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Midazolam Up to 71 Days Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration
Terminal Phase Elimination Half-Life (t1/2) of Caffeine Up to 71 Days Terminal phase elimination half-life (t1/2) of Caffeine
Terminal Phase Elimination Rate Constant (β) of Midazolam Up to 71 Days Terminal phase elimination rate constant (β) for Midazolam
Terminal Phase Elimination Half-Life (t1/2) of Midazolam Up to 71 Days Terminal phase elimination half-life (t1/2) of Midazolam
Maximum Observed Plasma Concentration (Cmax) of Caffeine Up to 71 Days Maximum observed plasma concentration (Cmax) of Caffeine
Time to Maximum Observed Plasma Concentration (Tmax) of Caffeine Up to 71 Days Time to maximum plasma concentration (Tmax) of Caffeine
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Caffeine Up to 71 Days Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration
AUC From Time 0 to Infinity (AUCinf) of Caffeine Up to 71 Days Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity
Maximum Observed Plasma Concentration (Cmax) of Warfarin Up to 71 Days Maximum observed plasma concentration (Cmax) of Warfarin
Time to Maximum Observed Plasma Concentration (Tmax) of Warfarin Up to 71 Days Time to maximum plasma concentration (Tmax) of Warfarin
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Warfarin Up to 71 Days Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration
AUC From Time 0 to Infinity (AUCinf) of Warfarin Up to 71 Days Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity
Terminal Phase Elimination Rate Constant (β) of Warfarin Up to 71 Days Terminal phase elimination rate constant (β) for Warfarin
Terminal Phase Elimination Half-Life (t1/2) of Warfarin Up to 71 Days Terminal phase elimination half-life (t1/2) of Warfarin
Maximum Observed Plasma Concentration (Cmax) of Omeprazole Up to 71 Days Maximum observed plasma concentration (Cmax) of Omeprazole
Time to Maximum Observed Plasma Concentration (Tmax) of Omeprazole Up to 71 Days Time to maximum plasma concentration (Tmax) of Omeprazole
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Omeprazole Up to 71 Days Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration
AUC From Time 0 to Infinity (AUCinf) of Omeprazole Up to 71 Days Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity
Terminal Phase Elimination Rate Constant (β) of Omeprazole Up to 71 Days Terminal phase elimination rate constant (β) for Omeprazole
Terminal Phase Elimination Half-Life (t1/2) of Metoprolol Up to 71 Days Terminal phase elimination half-life (t1/2) of Metoprolol
Time to Maximum Observed Plasma Concentration (Tmax) of Metoprolol Up to 71 Days Time to maximum plasma concentration (Tmax) of Metoprolol
Terminal Phase Elimination Half-Life (t1/2) of Omeprazole Up to 71 Days Terminal phase elimination half-life (t1/2) of Omeprazole
Maximum Observed Plasma Concentration (Cmax) of Metoprolol Up to 71 Days Maximum observed plasma concentration (Cmax) of Metoprolol
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Metoprolol Up to 71 Days Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration
AUC From Time 0 to Infinity (AUCinf) of Metoprolol Up to 71 Days Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity
Terminal Phase Elimination Rate Constant (β) of Metoprolol Up to 71 Days Terminal phase elimination rate constant (β) for Metoprolol
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (6)
University Clinical Research /ID# 216823
🇺🇸DeLand, Florida, United States
Southern California Res. Ctr. /ID# 216257
🇺🇸Coronado, California, United States
Clinical Trials of Texas, Inc /ID# 216277
🇺🇸San Antonio, Texas, United States
Atlantic Medical Research Group /ID# 227465
🇺🇸Margate, Florida, United States
Charite Research Organisation GmbH /ID# 218646
🇩🇪Berlin, Germany
The Chaim Sheba Medical Center /ID# 223959
🇮🇱Ramat Gan, Tel-Aviv, Israel